Cambridge, UK, 15 February 2024 – Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces the completion of the single ascending
Synairgen (AIM:SNG) appoints a permanent chief medical officer as they intensify drug development.
Synairgen PLC (AIM:SNG, OTC:SYGGF) has welcomed Dr. Marcin Mankowski, a veteran pharmaceutical physician and drug developer, as its chief medical officer with immediate effect.
Evgen Pharma (AIM:EVG) welcomes a new chairman and Chief Financial Officer (CFO).
Evgen Pharma PLC (AIM: EVG), renowned for its advancements in sulforaphane-based medicine, recently revamped its board structure.
Evgen Pharma (AIM:EVG) celebrates the potential new formulation of its leading candidate.
Evgen Pharma PLC (AIM: EVG) has revealed the conclusive data from its Phase 1b study, which evaluated the new enteric-coated tablet formulation of its primary drug, SFX-01.
Evgen Pharma (AIM:EVG) shifts focus towards more lucrative collaborations as their partnership with JuvLife concludes.
Evgen Pharma PLC (AIM: EVG), a clinical-stage pharmaceutical development firm, has disclosed the termination of its patent and knowledge licence agreement with JuvLife Ltd, a subsidiary of Juvenescence Ltd.
Polarean Imaging PLC (AIM:POLX) FDA Approves XENOVIEWT (Xe 129 hyperpolarized)
FDA Approves Polarean’s XENOVIEW™ (xenon Xe 129 hyperpolarized) for use with MRI for the evaluation of lung ventilation
Evgen Pharma PLC (AIM:EVG) Study started of new SFX-01 tablet formulation
First healthy volunteers dosed on schedule
Evgen Pharma PLC (AIM:EVG) SFX-01 licensing deal for up to $160.5m
SFX-01 licensing deal for up to $160.5m in milestone payments expands lead asset into neurodevelopmental disorders
Synairgen plc (AIM:SNG) Synairgen presents at ATS 2022
Synairgen presents detailed analysis of Phase 3 SPRINTER trial evaluating SNG001 in hospitalised COVID-19 patients at ATS 2022
Evgen Pharma PLC (EVG.L) Progress with UK and US regulators for 2022 trials
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the
Synairgen plc (SNG.L) SNG001 progresses to Phase 3 of ACTIV-2 trial
Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored
Evgen Pharma PLC (EVG.L) Publication of data in glioblastoma cells
Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data